Objective: Multiple primary lung cancers are detected with increasing frequency, but the ideal strategy for diagnosis and treatment remains disputable. This study evaluated both clinical characteristics and genetic alterations to investigate the appropriate strategy for patients with multiple primary lung cancer.
Results: There were 24, 35, and 37 patients in groups A, B, and C, respectively. During follow-up, 23 patients had recurrence. The 5-year recurrence-free survival was 100% in patients with multiple ground-glass opacity, 68% in those with 1 solid lesion, and 51.4% in those with 2 solid tumors (P ¼ .001). Eighteen patients died of lung cancer. The 5-year overall survival was 100% in group A, 80.5% in group B, and 59.9% in group C (P ¼ .002). A total of 77 driver mutations were detected in 61 of the 82 lesions. A high rate of discordance of genetic alterations (89.7%) was found between cancers within individual patients. Two patients in group C had concordant driver mutations between the 2 lesions, and both of them harbored tumor recurrence.
Conclusions: A high discordance of driver mutations between tumors in individual patients and a favorable prognosis were identified in patients with multiple primary lung cancers diagnosed by clinical-pathologic criteria, which support different strategies from those with metastatic disease. (J Thorac Cardiovasc Surg 2018;155:371-9)
The OS of the 3 groups of patients after resection.
Central Message
High variability of driver mutations between tumors and favorable prognosis were identified in patients with MPLCs diagnosed by clinicalpathologic criteria.
Perspective
We compared MPLCs from both clinical and genetic aspects concurrently. High discordant rate of mutations confirmed that these MPLCs likely developed as independent primaries rather than intrapulmonary metastasis, especially in patients with multiple GGOs. The favorable prognosis after resection supports surgical resection as a reasonable approach.
See Editorial Commentary page 380.
See Editorial page 361.
The first criteria for the diagnosis of multiple primary lung cancer (MPLC) were established by Martini Chest Physicians (ACCP). 2 However, there is a lack of high-level, evidence-based studies; therefore, determining the optimal management of patients with MPLC is still a difficult clinical decision. For multiple solid lung cancers, many clinicians are more likely to follow standard TNM staging guidelines in the core components of the American Joint Committee on Cancer staging system, in which patients with additional tumor nodules in the same lobe would be staged as T3; an ipsilateral tumor in a separate lobe would be considered as T4, and a contralateral tumor in a separate lobe would be M1a. 3 However, this staging strategy could lead to inappropriate classification of patients with MPLCs, who may benefit from surgical resection despite the designation of T4 or M1a.
Moreover, the frequency of recorded multiple pulmonary nodules, especially multiple ground-glass opacities (GGOs), has steadily increased in recent years because of improved resolution of computed tomography (CT) imaging. The statement from the Fleischer Society and the consensus of the International Association for the Study of Lung Cancer considered multiple GGOs as MPLCs rather than intrapulmonary metastasis, 4 but there is lack of evidence to reliably identify multiple GGO lesions as clonal or otherwise. Few studies have investigated the characteristics of GGO and solid lung nodules that exist concurrently. [5] [6] [7] These conditions raise the clinical controversy of how MPLCs should be managed. 8 Most surgeons treat them by their personal experience. Some recent studies that analyzed clinical characteristics have indicated that surgical resection of selected MPLC is associated with better than expected long-term survival. 9, 10 Other studies explored the application of genomic profiling in managing patients presenting with MPLC. 11 Few research studies have evaluated this problem from both clinical and genetic aspects to understand more clearly the characteristics of MPLC. This study aims to provide a comprehensive description of the clinical features and genetic alterations in patients with MPLCs to provide benchmarks on the treatment and prognosis of such patients.
MATERIALS AND METHODS Patients
From January 2007 to April 2014, 1561 consecutive patients with lung cancer underwent resection in our department. Patients who had at least 2 malignant resected nodules were eligible for selection in this study. On the basis of clinical-pathologic criteria (Martini and Melamed's 1 and the ACCP modified guidelines with histologic assessment by a pathologist), the inclusion criteria of this study are different histologic type or arising from a separate focus of carcinoma in situ; and same histology, anatomically separated: cancer in different lobes and no N2,3 involvement and no systemic metastases. Patients who had more than 1 lesion resected, but for whom pathologic evaluation demonstrated only 1 of the lesions to be malignant, were excluded. Figure 1 shows the detailed flow of this study. Finally, 96 patients (6.1%) were included. All of the patients received contrast-enhanced thoracic CT scans before surgery. Other routine preoperative examinations included chest radiograph, cardiopulmonary function tests, abdominal and adrenal gland ultrasonography or CT, brain magnetic resonance imaging or CT, and a bone scan. If mediastinal lymph node enlargement (!1 cm) was demonstrated on chest CT, endobronchial ultrasound transbronchial needle aspiration or mediastinoscopic biopsy was performed first. Positron emission tomography/CT was not mandatory in every patient. Written informed patient consent was obtained for tissue analysis before surgery, and the protocol of this retrospective study was approved by the Institutional Review Board of Peking University People's Hospital.
We classified these multiple lung cancer nodules to the primary nodule (PN), secondary nodule (SN), and other lesions. The PN was defined as the main tumor to be surgically resected decided by the surgeons, which primarily depends on its radiologic invasiveness and tumor size. The SN was defined as the secondary tumor to be resected. According to the ratio of maximum diameter of consolidation to the maximum tumor diameter from the lung window (consolidation/tumor ratio [CTR]) on thin-section CT, 96 cases were classified into 3 groups: group A (both PN and SN were GGO-dominant nodules, CTR 0.5), group B (PN was solid-dominant, CTR >0.5; SN was GGO-dominant nodule), and group C (both PN and SN were solid-dominant nodules). CTR of 0.5 as a cutoff depends on the results of several published studies, [12] [13] [14] [15] which considered CTR less than 0.5 could be used to radiologically define noninvasiveness precisely.
Our indication to manage multiple GGO nodules was basically according to the statement from the Fleischer Society. 4 Patients with at least 1 of the multiple GGOs larger than 5 mm as a dominant lesion would receive surgery. Patients with multiple pure GGOs all measuring 5 mm or less were excluded from surgery and managed with follow-up, unless they were so anxious about cancer that they requested surgery as opposed to follow-up, despite the fact that the nodules were noninvasive.
Surgical Approach
According to different characteristics of multiple pulmonary nodules, surgical procedures were performed discriminately. Our basic treatment strategy for synchronous multiple pulmonary nodules was as follows. (1) The site and size of the nodule, radiologic characteristics, and estimated postoperative respiratory function were initially assessed. (2) If tumors were ipsilateral, single-stage operation should be performed. Wedge resection or segmentectomy was preferred when the nodules were all pure GGOs. In cases with multiple subsolid nodules with a dominant solid lesion, lobar resection of the dominant nodule along with limited resection to the other scattered nodules was the common procedure. All accessible ipsilateral nodules were resected at the same time, unless the GGOs were deeply embedded and could not be resected by wedge. (3) When tumors were contralateral, 2-stage surgical treatment was commonly recommended. For some young patients with good pulmonary function, 1-stage surgical treatment was also a choice. If contralateral lesions were all small pure GGOs, a wait-and-see approach was undertaken and monitored for growth and invasion. Most patients (90.6%) underwent lung resection via video-assisted thoracoscopic surgery.
Clinical Variables
The 7th American Joint Committee on Cancer edition of TNM staging was used in our study. We collected clinical variables for patients, including age, gender, tumor history, smoking history (<100 cigarettes defined as nonsmokers), pulmonary function, TNM stage, tumor histology, and tumor location and size measured by CT. Chest CT scan and abdominal ultrasound/CT are performed on follow-up visits every 6 months after 
Preparation of Tumor Tissue DNA and RNA
Eight patients with different tumor histology between the 2 lesions were excluded for mutational analysis. Fourteen patients whose tissue blocks had been used before this study were excluded; 5 patients' blocks were lost; 7 patients only preserved 1 of the multiple lesions; 14 patients received surgery more than 5 years ago were excluded because of concerns about the quality of RNA; and 9 patients were excluded because of the small amount of tumor cells in preserved tumor samples after review by the pathologist. After all exclusions, 82 samples originating from 39 patients were available for mutational analysis. The QIAamp DNA FFPE Tissue Kit (QIAGEN, Valencia, Calif) was used to extract DNA from formalin-fixed, paraffin-embedded tissue. The Recover ALL Total Nucleic Acid Isolation Kit (1407077) was used for RNA extraction from fresh tumor tissue or formalin-fixed, paraffin-embedded tissue. Finally, DNA was quantified with the Qubit 2.0 Fluorometer and Qubit dsDNA HS Assay kit (Life Technologies, Carlsbad, Calif) according to the recommended protocol.
Driver Mutation and Fusion Analysis
Somatic mutations in epidermal growth factor receptor (EGFR), Tp53, KRAS, PIK3CA, and BRAF were combined for analysis. Initial data from the sequencing runs were processed using Torrent Suite 
Statistical Analysis
Differences in patients' characteristics among the 3 surgery groups were evaluated using chi-square tests for categoric variables and 1-way analysis of variance tests for continuous variables. Abnormal distributed continuous data were evaluated by Kruskal-Wallis test. Chi-square test or Fisher exact test was used to measure correlations between driver mutations with pathologic or radiologic features. The RFS and OS were evaluated by Kaplan-Meier survival analysis. The log-rank test was used to assess significance of survival distributions among groups. All tests were 2-sided. For statistical analysis, we used the SPSS Statistics version 23 (IBM, Chicago, Ill).
RESULTS
There were 24 patients in group A, 35 patients in group B, and 37 patients in group C. Significant differences were found in age, sex, smoking history, and tumor size among the 3 groups (Table 1) . No serious postoperative complications or perioperative death was observed in any group. The pathologic characteristics and treatment methods are shown Table 2 . More patients in group A had adenocarcinoma in situ or minimally invasive adenocarcinoma and treated with sublobar resections, whereas more patients in group C had invasive adenocarcinomas and underwent more lobar resections. The histology types of the 2 tumors were different in the 2 patients with positive N2 lymph nodes. Some 34.4% of patients had residual GGOs after surgery, and most of them (81.9%) were in groups A and B. No difference of the fate of residual GGOs was found among the 3 groups. In the 5 patients with increased residual GGOs, 3 underwent surgical resection, 1 underwent radiotherapy, and 1 received targeted therapy. The median RFS is 37.5 months (interquartile range, 26-49.5). A total of 23 recurrences have been identified during follow-up. The recurrence locations are shown by group in Table 2 . The 3-and 5-year RFS were 82.9% and 71.3%, respectively. Compared with patients in group C, group A and group B patients had significantly less tumor recurrence (P ¼ .001 and .032 for RFS comparing group A with C and group B with C, respectively) ( Figure 2) .
The median OS is 43 months (interquartile range, 32.3-54.5). A total of 18 patients died of lung cancer (2 in group 2, 16 in group 3). The 3-and 5-year OS were 90.5% and 75.6%, respectively. Group A and group B patients were significantly more likely to be alive compared with patients in group C (group A vs group C, P ¼ .009; group B vs group C, P ¼ .013) (Figure 3 ).
Driver Mutation Analysis and Comparison With Radiologic Features
A total of 77 driver mutations were detected in 61 of the 82 lesions (74.4%). EGFR was the most common and was present in 43 lesions (52.4%). Among them, 10 were exon 19 deletions, 28 were L858R missense mutation, 4 had other EGFR mutations, and 1 had concomitant exon 19 deletion and L858R mutation. KRAS mutations were found in 5 lesions (6.1%). Four samples (4.9%) harbored EML4-ALK fusions. No PIK3CA mutation was found in all the lesions. Twelve lesions had 2 concomitant driver mutations. Two lesions had 3 concomitant driver mutations. The detailed mutations are shown in Figure E1 .
The distribution of mutations according to histology and radiologic subgroups is shown in Table 3 . The positive rate of mutations in the adenocarcinoma in situ/ minimally invasive adenocarcinoma subgroup was not significantly different than in the invasive subgroup (P ¼ .269). The incidence rate of mutations among groups 1, 2, and 3 was also not significantly different (P ¼ .374). In accordance with previous studies showing that series mutations such as EGFR, KRAS, and TP53 could occur in an early stage of pulmonary development, [16] [17] [18] we also found these mutations in those early lesions diagnosed as adenocarcinoma in situ/minimally invasive adenocarcinoma.
The discordant frequency rate of the driver mutation distribution was 89.7% (35/39) in the whole population, whereas it was 94.6% (35 of 37) in the patients harboring at least 1 of the detected driver mutations. If calculating EGFR alone, the discordant rate of driver mutations was 82% (32/39) in the whole population.
All of the 23 patients who received genetic detection in groups A and B had discordant driver mutations between the 2 lesions except 1 patient in group B had no detectable mutations, and none of them had tumor recurrence. In comparison, 2 patients in group C had concordant driver mutations between the 2 lesions, and both of them had tumor recurrence. The 1 patient who exhibited consistent EML4(13)-ALK(20) fusion had intrapulmonary metastasis 12 months after surgery and was still alive by the end of follow-up. In the other patient who had a consistent BRAF V600E mutation, lymph-node metastasis occurred 15 months after surgery and the patient died in 21 months. In the other 14 patients, 1 had no detectable mutation and 13 had discordant driver mutations, in whom 2 had tumor recurrence. There was a significant difference in the recurrence rate between patients who had discordant driver mutations and consistent driver mutations (5.7% vs 100%, P ¼ .009).
DISCUSSION
MPLCs can be multiple GGOs or GGO mixed with solid tumors or multiple solid lung cancers. We separated patients with MPLC into 3 groups according to radiologic CTR and compared clinical features, long-term outcomes, and gene features. A high discordant rate of mutations and the favorable prognosis after resection support these tumors more likely developed as independent primaries rather than intrapulmonary metastasis, especially in multiple GGOs. As far as we know, this is the first study to compare different types of MPLC from both clinical and genetic viewpoints concurrently (Video 1).
In group A, no recurrence or death occurred, and this excellent prognosis in multiple GGOs is similar to results in previous studies. 15, 19, 20 Because of the increasing occurrence of multiple GGOs, we have been experiencing a more common situation in which patients present with a predominant solid nodule along with scattered GGOs (group B). Castiglioni and colleagues 21 compared patients with a solitary lesion with patients who have a dominant lesion and additional nodules. The results showed no statistically significant differences in 5-year DFS (82.3% vs 83.8%, P ¼ .254) and OS (86.7% vs 93.8%, P ¼ .096) between the 2 groups. Similar results were presented in the study by Gu and colleagues, 22 who showed that patients who underwent resection of the dominant invasive adenocarcinoma and wedge resection of accessible GGOs had favorable survival. Our results also showed a favorable prognosis in group B, which indicated that FIGURE 2. RFS of the 3 groups of patients after resection. A significant difference was found among the 3 groups (P ¼ .001). Lighter lines indicate 95% confidence intervals. RFS, Recurrence-free survival; CI, confidence interval. scattered GGOs did not behave like metastatic lesions. In the genetic analysis, our results are in concordance with Wu and colleagues' study, 17 which analyzed 8 driver mutations and found a high discrepancy of 80% among patients with GGOs, and supports the hypothesis of field cancerization, 23 which proposes that cells in the entire lung epithelium that are similarly exposed to carcinogens become aberrant. Combined with survival data, GGOs are more likely to arise from different primary clones. Therefore, clinicians and pathologists should be careful not to regard patients who have a solid nodule along with GGOs as exhibiting intrapulmonary metastasis and thereby misinterpret the TNM stage.
The outcomes of patients with multiple solid lung cancer reported in the last 25 years vary widely (0%-70%). 24 Fabian and colleagues 25 suggested that an appropriate preoperative assessment was critical in patient selection, and the overall 5-year survival of MPLC was 53%. In view of the strict inclusion and exclusion criteria, their report may reflect the true expected outcomes for patients undergoing resection of MPLC who are N2 negative. Likewise, we found the overall 5-year survival of group C is 59.9%, which is better than for intrapulmonary metastasis lung cancer. Therefore, the results of our study are consistent with survival after surgical resection as reported by others for all the 3 types of MPLC. The favorable prognosis after resection supports surgical resection as a reasonable approach in patients with MPLC diagnosed by clinical-pathologic criteria.
In group C patients who received genetic analysis, 2 of them exhibited consistent driver mutations, which indicated they were more likely to have intrapulmonary metastasis, and the follow-up outcome confirmed this speculation. Many attempts have been made to separate primary lung cancers from metastasis. Martini and Melamed's 1 criteria and ACCP guidelines are most commonly used. Martini and Melamed's criteria were established according to clinical characteristics 40 years ago, at which time no genetic details were considered. The ACCP guidelines differ slightly from Martini and Melamed's criteria and do not take imaging characteristics such as GGO into consideration. Travis and colleagues 26 have investigated comprehensive histologic assessment to improve the diagnostic accuracy of MPLCs. However, the data on comprehensive histologic assessment are based on a limited number of patients and lack a gold standard.
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Comprehensive histologic assessment depends too much on the experience of the pathologists, such as to differentiate the percentage of the major histologic subtype and other histologic subtype, so that a similar histologic subtype appearance does not necessarily define lesions as metastases. Our study revealed that although in many cases 
Study Limitations
First, this is a retrospective study based on Chinese patients. A prospective study is needed, and our results need to be validated in western patients because the clinical characteristics and population genomic features of lung cancer were discrepant between Chinese and western patients. Second, the genomic analyses using the 8 high-frequency driver genes represent a only part of the genetic features. It would be more accurate by using whole genome or exome sequencing. Third, only a portion of the patients in this study had genomic analyses, and the follow-up time span is not long enough to appropriately assess long-term survival.
CONCLUSIONS
Genetic and survival analyses confirm all multiple GGOs, and the majority of multiple solid tumors considered as multiple primaries by clinical criteria are likely to be independent primaries, which support different strategies from those with metastatic disease.
Webcast
You can watch a Webcast of this AATS meeting presentation by going to: http://webcast.aats.org/2016/Video/ Wednesday/05-18-16_Ballroom_IV_0803_Chen-800.mp4.
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Authors have nothing to disclose with regard to commercial support. Dr K. Chen (Beijing, China). In Martini and Melamed's 1 criteria, there are no criteria for the adenocarcinoma subtype because they were established 40 years ago, and then in 2013 the ACCP guidelines show that the adenocarcinoma subtype is 1 of the criteria. For some patients, it works very well. For example, the 2 lesions, if 1 is lepidic-dominant and the other is micropapillary-dominant, we can say they are independent primaries. However, in other patients, if both of the lesions have a similar subtype, maybe both of the lesions have papillary-dominant tumors, and it may be difficult. For example, in our study, group 3, there are 2 patients who had concordant mutations. Both of them had the solid dominant subtype located in different lobes and no lymph-node metastasis. So it is difficult to differentiate primary or metastatic by clinical criteria. By genetic mutation analysis, we can get it. In 4 recent online articles in the Journal of Thoracic Oncology this year, it was proposed that a clearly different comprehensive histology assessment is considered to be independent primaries. However, these clearly different criteria include the major subtype, the minor subtype, and the cytologic and stromal features, and perhaps more time and experience of the pathologists. I think genomic analysis may work sometimes. Dr Onaitis. It seems like this is a rich dataset to try to tease out the sequence of mutations. For instance, EGFR might be an early mutation in ground-glass lesions and things like p53 might be in solid lesions. Did you do any analysis like that to look at radiologic appearance or survival based on the mutation?
Dr Chen. Yes, we have the data about the genetic mutations and the correlation of the mutations and the radiographic features. A total of 11 lesions had the TP53 mutation, and 9 of them, 82%, were in solid tumors. For the EGFR mutation, 44 lesions had the EGFR mutation, and more were in GGO tumors. A previous study showed that EGFR mutation occurs in early-stage adenocarcinoma development. In the mutation of EML4-ALK fusion, 4 lesions had EML4-ALK fusion, and 2 (50%) of them happened in GGO lesions, which also showed that EML4-ALK mutation may play an important role in tumor initiation and early-stage development, much like EGFR.
Dr D. Finley (Lebanon, NH). Going back to Martini and Melamed's 1 criteria, we updated those by looking at histologic subtyping, and then there have been 2 analyses pooling the data across the United States to see whether you can use the standard criteria of Martini and Melamed with an updated histologic subtyping as a way to differentiate between synchronous primaries and metastatic disease, showing that, in actuality, you can with a high sensitivity and specificity. Bill Travis then also looked at specifically mutational analysis, comparing it with histologic subtyping, and found that in patients who had identical molecular changes, there were different histologic subtypings, and those patients had survival that was similar to synchronous primaries and not metastatic disease. So I don't think we are there yet to say that mutational analysis in and of itself is enough to determine whether something is a metastasis or not because we know that you can have 2 tumors that start de novo with the same molecular changes, although they are not metastatic disease. Will you comment on that given the data that you are presenting?
Dr Chen. One of the limitations of our study is that we just detected high-frequency mutations. Maybe the 2 tumors have the same mutations, but they may still be independent primaries because we just analyzed some of the mutations. These high-frequency mutations just represent a part of the genomic information. I think maybe for more details, the whole genome or whole exome analysis will work better, but it is so expensive.
Dr Keshavjee. It seems like your article would be enhanced by having the pathologic review added to what you have. That would be easy to do going back. You would have to make pathologists do some extra work though.
Dr Chen. Yes. 
